Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 31 people who received a treatment called taliglucerase alfa. Thirty of the 31 participants completed the study, with one person not finishing. The trial was measuring several things in people's blood and organs, with the main focus being haemoglobin levels — haemoglobin is the protein in red blood cells that carries oxygen around the body. The study also tracked platelet counts (tiny blood cells that help with clotting), as well as the size of the spleen and liver, both of which can be affected in the condition being studied. The reported data shows that haemoglobin levels across the measurement points were 13.5, 13.3, 13.3, and 13.4 grams per decilitre (g/dL), a common unit for measuring haemoglobin in blood. For platelet counts, the reported figures across measurement points were approximately 161,137, 150,800, 157,586, and 161,167 platelets per cubic millimetre of blood. The reported data shows spleen volume, measured by MRI scan, was 720.5 millilitres at one time point and 654.7 millilitres at another. Liver volume was reported as 1,766 millilitres and 1,716 millilitres across two time points. The data does not include labels specifying exactly when each of these measurements was taken, so precise timing details were not reported in the structured results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 24950666) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Gaucher Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male or female, aged 2 years or older
- You have been diagnosed with Gaucher disease, confirmed through a specific enzyme activity test
- Your Gaucher disease is currently stable
- You have been receiving treatment with imiglucerase (Cerezyme®) for at least 2 years, and your dose and schedule have stayed the same for at least the last 6 months (exceptions may apply if there was a drug shortage)
- You are able to sign a written consent form agreeing to take part
Who may not be able to join:
- You are currently taking another experimental or trial drug for any condition
- You have a history of being allergic to carrots
- You have a history of being allergic to beta-lactam antibiotics (a common type of antibiotic, such as penicillin)
- You have previously had a reaction during an infusion of Cerezyme® or Ceredase® that was thought to be allergic, or you currently take medication before infusions to prevent such reactions
- You have HIV, hepatitis B (HBsAg), or hepatitis C
- You have anemia caused by a deficiency in iron, folic acid, or vitamin B12 that has not been treated or resolved
- You have another significant health condition that could affect how your body responds to the trial treatment (confirm with trial site)
- You have any medical, emotional, or psychological condition that the trial doctor believes would make it difficult for you to follow the study requirements (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Hemoglobin
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.